XENE Stock Summary and Trading Ideas (Xenon Pharmaceuticals - Common Shares | NASDAQ:XENE)

Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.

Xenon Pharmaceuticals - Common Shares trades on the NASDAQ stock market under the symbol XENE.

As of October 5, 2026, XENE stock price declined to $37.29 with 268,162 million shares trading.

XENE has a beta of 0.43, meaning it tends to be less sensitive to market movements. XENE has a correlation of 0.01 to the broad based SPY ETF.

XENE has a market cap of $3.61 billion. This is considered a Mid Cap stock.

Last quarter Xenon Pharmaceuticals - Common Shares reported $0 in Revenue and -$1.11 earnings per share. This fell short of revenue expectation by $-937,500 and exceeded earnings estimates by $.05.

In the last 3 years, XENE traded as high as $72.66 and as low as $26.74.

The top ETF exchange traded funds that XENE belongs to (by Net Assets): IWM, IWO, VTWO, IBB, TCAF.

XENE has underperformed the market in the last year with a price return of -4.9% while the SPY ETF gained +16.5%. XENE has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -38.8% and -6.2%, respectively, while the SPY returned +4.0% and +1.4%, respectively.

XENE support price is $36.94 and resistance is $39.11 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that XENE shares will trade within this expected range on the day.